1. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen
- Author
-
Laura Galli, Enzo Boeri, Nicola Gianotti, Adriano Lazzarin, Hamid Hasson, David Nauwelaers, Anna Danise, Richard M. W. Hoetelmans, Antonella Castagna, Castagna, Antonella, Gianotti, N, Galli, L, Danise, A, Hasson, H, Boerr, E, Hoetelmans, R, Nauwelaers, D, and Lazzarin, A.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lopinavir/ritonavir ,HIV Infections ,Microbial Sensitivity Tests ,Pyrimidinones ,Biology ,Gastroenterology ,Lopinavir ,Treatment experienced ,Virological response ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Protease inhibitor (pharmacology) ,Sida ,Pharmacology ,Ritonavir ,HIV Protease Inhibitors ,Viral Load ,biology.organism_classification ,Virology ,CD4 Lymphocyte Count ,Regimen ,Phenotype ,Infectious Diseases ,Multivariate Analysis ,HIV-1 ,Drug Therapy, Combination ,Female ,Drug Monitoring ,medicine.drug - Abstract
Objective To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients. Design We calculated the NIQ for 59 patients who completed 48 weeks’ treatment and assessed the factors predicting a week-48 virological response. Methods The NIQ was calculated by dividing each subject's IQ (LPV Ctrough/fold change in LPV susceptibility, as assessed by VirtualPhenotype™) by a reference IQ (mean population LPV Ctrough/fold change in LPV IC50, as assessed by VirtualPhenotype™). HIV-1 RNA was assessed by NASBA (quantification limit: 80 copies/ml). The general linear model and multiple logistic regression, respectively, were used to estimate the independent predictors of a change in viral load and HIV-1 RNA Results The median (interquartile range) baseline levels of CD4+ cells and HIV-1 RNA were 251 (141–385) cells/μl and 4.85 (4.49–5.23) log10 copies/ml, respectively. The median NIQ was 2.2 (0.5–14). At week 48, the median decrease in HIV-1 RNA was 1.4 (0.59–2.79) log10 copies/ml ( PConclusion The LPV NIQ independently predicts virological responses to an LPV/RTV-containing regimen in highly treatment-experienced HIV-1-infected patients.